Verastem(GB:0LOV)
$6.85-0.70 (-9.27%)
GB:0LOV
Verastem stock drug pipeline
$6.85
At close:-0.70 (-9.27%)
Verastem (0LOV) Drug Pipeline
3 Followers
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Verastem Inc (GB:0LOV) have in its pipeline
Verastem GB:0LOV is currently developing the following drugs: Cetuximab, Vs-7375, Panitumumab, Cetuximab + Mfolfox6, Vs-7375, Cetuximab, Vs-7375, Avutometinib + Defactinib, Paclitaxel, Avutometinib, Defactinib, Pegylated Liposomal Doxorubicin, Letrozole, Anastrozole, Avutometinib And Defactinib In Combination With Gemcitabine And Nab-Paclitaxel, Avutometinib And Adagrasib, Vs-6766, Avutometinib And Sotorasib, Avutometinib And Sotorasib And Defactinib, Avutometinib, Avutometinib And Defactinib, Part A - Vs-6063, Part A - Avelumab, Defactinib, Part B, Cohort 1- Vs-4718, Nab-Paclitaxel, Gemcitabine, Part B, Cohort 2- Vs4718, Nab-Paclitaxel, Gemcitabine, Part A- Vs-4718, Nab-Paclitaxel, Gemcitabine, Vs-5584 And Vs-6063, Vs-4718, Vs-6063, Vs-5584, Paclitaxel, Defactinib, Pf-04554878. These drug candidates are in various stages of clinical development as the company works toward FDA approval.

